Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-09457b67378eccc379f945623f721bcb"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-09457b67378eccc379f945623f721bcb"/>
<resource>
<Composition>
<id value="composition-en-09457b67378eccc379f945623f721bcb"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-09457b67378eccc379f945623f721bcb"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-09457b67378eccc379f945623f721bcb</b></p><a name="composition-en-09457b67378eccc379f945623f721bcb"> </a><a name="hccomposition-en-09457b67378eccc379f945623f721bcb"> </a><a name="composition-en-09457b67378eccc379f945623f721bcb-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1390/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - inbrija</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/19/1390/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp09457b67378eccc379f945623f721bcb"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - inbrija"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Inbrija is and what it is used for</li><li>What you need to know before you use Inbrija</li><li>How to use Inbrija</li><li>Possible side effects</li><li>How to store Inbrija</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What inbrija is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What inbrija is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>The active substance in Inbrija is levodopa. Inbrija is a medicine used by inhalation for treating the worsening of your symptoms during the off periods of Parkinson s disease.</p><p>Parkinson s disease affects your movement and it is treated with a medicine that you take regularly. During off periods your usual medicine does not control the condition well enough and movement is likely to be more difficult.</p><p>You should continue taking your main medicine for Parkinson s disease and use Inbrija to control worsening of symptoms (such as inability to move) during off periods.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take inbrija"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take inbrija"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use Inbrija:</p><ul><li>if you are allergic to levodopa or any of the other ingredients of this medicine (listed in section 6).</li><li>if you get blurred vision, red eyes, severe eye and head pain, halos around lights, pupils of your eyes that are larger than normal size and feel sick. If you have any of these symptoms, you may have a eye condition called narrow angle glaucoma, which occurs suddenly: do not take Inbrija and get urgent medical attention.</li><li>if you have a rare tumour of the adrenal gland called phaeochromocytoma.</li><li>if you are taking certain antidepressant medicines called non-selective MAO inhibitors (e.g. isocarboxazid and phenelzine). You must stop taking these medicines at least 14 days before starting treatment with Inbrija. See also under Other medicines and Inbrija .</li><li>if you have previously suffered from neuroleptic malignant syndrome, a life-threatening reaction to certain medicines used to treat severe mental disorders or if you have suffered from non-traumatic rhabdomyolysis, a rare muscle disorder in which damaged muscle breaks down rapidly.</li></ul><p>Warnings and precautions Get urgent medical help if you have tremors, agitation, confusion, fever, rapid pulse, or dizziness and fainting upon standing up, or you notice that your muscles get very rigid or jerk violently. These may be symptoms of withdrawal-emergent hyperpyrexia . For more information see section 4. Talk to your doctor or pharmacist before using Inbrija if you have, or have ever had, or you develop:</p><ul><li>asthma, breathing difficulties like chronic obstructive pulmonary disease (COPD) or other long- term lung diseases or breathing problems;</li><li>any form of severe mental disorder like psychosis;</li><li>a heart attack, or heart beat problems. Your doctor will monitor you closely during start of treatment;</li><li>an ulcer in your stomach or intestines;</li><li>an eye condition called glaucoma, because the pressure in your eyes may need to be monitored;</li><li>severe problems with your kidneys;</li><li>severe problems with your liver.</li></ul><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Inbrija.</p><p>Talk to your doctor or pharmacist if you develop any of the symptoms below whilst using Inbrija:</p><ul><li>sudden sleep attacks or sometimes feeling very sleepy;</li><li>changes in or worsening of your mental state, which may be severe such as psychotic and suicidal behaviour;</li><li>hallucinations, along with being confused, unable to sleep and excessive dreaming. Abnormal thinking including anxiety, depression, being agitated, being paranoid, delusional, or disorientated, aggressive behaviour and delirious;</li><li>worsening of any breathing symptoms or having a respiratory infection;</li><li>urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or an increase in sexual thoughts or feelings. Your doctor may need to review your treatments.</li><li>new or increased abnormal body movements (dyskinesia);</li><li>feeling dizzy when getting up (low blood pressure);</li><li>melanoma (a type of skin cancer) or suspicious skin growths or marks.</li></ul><p>If you need to have surgery, tell your doctor that you are using Inbrija.</p><p>Tests You may need to have tests on your heart, liver, kidney, and blood cell tests during long-term treatment with your medicines. If you need to have tests on your blood or urine, tell your doctor or nurse that you are taking Inbrija. This is because the medicine may affect the results of some tests.</p><p>Children and adolescents The use of Inbrija is not recommended in patients under 18 years of age.</p><p>Other medicines and Inbrija Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because other medicines can affect the way Inbrija works.</p><p>Do not use Inbrija if you have taken medicines called non-selective MAO inhibitors for treating depression in the last 14 days. These medicines include isocarboxazid and phenelzine. If this applies to you, do not take Inbrija and ask your doctor or pharmacist for advice.</p><p>Tell your doctor or pharmacist if you are taking:</p><ul><li>medicines for your Parkinson s disease called selective MAO inhibitors such as rasagiline, selegiline and safinamide, COMT inhibitors such as entacapone, tolcapone and opicapone, or anticholinergics such as orphenadrine and trihexyphenidyl;</li><li>medicines for mental conditions including schizophrenia, such as benperidol, haloperidol, risperidone, chlorpromazine, fluphenazine decanoate, phenotiazine, butyrophenone, or trifluoperazine;</li><li>metoclopramide to treat nausea;</li><li>isoniazid, an antibiotic to treat tuberculosis;</li><li>medicines for high blood pressure, as the dose may need to be adjusted;</li><li>medicines for depression called tricyclic antidepressants such as clomipramin, desipramin, or doxepin;</li><li>amantadine to treat flu or your Parkinson s disease.</li></ul><p>Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Treatment with Inbrija is not recommended during pregnancy and in women of childbearing age who do not use contraception.</p><p>Women should not breast-feed during treatment with Inbrija.</p><p>Driving and using machines Inbrija can cause excessive drowsiness, dizziness and sudden sleep attacks. If this happens to you, do not drive or use tools or machines. You must be sure that you do not get sudden sleep attacks, dizziness and drowsiness before you drive again or use machines. You could put yourself or others at risk of serious injury or death.</p></div>
</text>
</section>
<section>
<title value="3. How to take inbrija"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take inbrija"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Before starting Inbrija, you must be taking regular treatment for Parkinson s disease combining a so- called dopa-decarboxylase inhibitor with levodopa.</p><p>The recommended dose of Inbrija is 2 capsules to treat each off period. Do not use more than 2 capsules for each off period. You can use 2 capsules up to five times a day.</p><p>The maximum dose of Inbrija is 10 capsules per day.</p><p>Important information before you use Inbrija:</p><ul><li>Inbrija capsules must not be swallowed.</li><li>This medicine is for use by inhalation only.</li><li>The capsules must only be removed from the blister pack immediately before use.</li><li>Two capsules of medicine should be inhaled to get the full dose.</li><li>The medicine must be used only with the Inbrija inhaler device.</li><li>When you open a new carton, always use the new inhaler supplied.</li><li>Your doctor or pharmacist will show you how to use your medicine correctly.</li></ul><p>Please see the Instructions for use at the end of this leaflet on how to use your medicine with the provided inhaler.</p><p>If you use more Inbrija than you should If you use more Inbrija than you should (or someone accidentally swallows Inbrija) get medical help immediately. You may feel confused or agitated, and your heart rate may be slower or faster than normal.</p><p>If you forget to use Inbrija Use Inbrija only during an off period. If the off period has passed, do not use Inbrija until the next off period.</p><p>If you stop using Inbrija Do not stop using Inbrija without checking with your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Get urgent medical help if you have an allergic oedema with symptoms including hives (nettle rash), itching, rash, swelling of your face, lips, tongue, or throat. This may cause difficulties in breathing or swallowing.</p><p>Get urgent medical help if your muscles get very rigid or jerk violently, you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. These can be symptoms of neuroleptic malignant syndrome (NMS, a rare severe reaction to medicines used to treat disorders of the central nervous system) or rhabdomyolisis (a rare severe muscle disorder).</p><p>Get urgent medical help if you have bleeding in your stomach or intestines which may be seen as blood in your faeces or darkened faeces.</p><p>The following side effects may happen with this medicine: Very common (may affect more than 1 in 10 people):</p><ul><li>cough</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>new or increased abnormal body movements (dyskinesia);</li><li>infections of nose, sinuses, throat or lungs;</li><li>change in colour of your mucus;</li><li>discoloured (i.e. not clear) nasal mucus;</li><li>irritation in throat or itchy throat;</li><li>feeling sick (nausea); vomiting;</li><li>being prone to falls.</li></ul><p>Other side effects you may experience of which the frequency is not known include:</p><ul><li>sensation of choking associated with the drug powder impacting the back of the throat, immediately after use</li><li>skin cancer;</li><li>lack of red blood cells so you are pale and feel tired; being more prone to infections because of a lack of white blood cells; lack of blood platelets which can lead to bruising and a tendency to bleed;</li><li>decreased appetite;</li><li>confusion; hallucinations; depression; anxiety; bad dreams; unable to sleep; abnormal thinking and perceptions, losing touch with reality; feeling agitated; suicidal; being disorientated; exaggerated feeling of happiness; increased sex drive; grinding of teeth; feeling paranoid and delusional;</li><li>movement disorder in which a person's muscles contract uncontrollably; sudden, sometimes unpredictable changes in symptoms, due to the return of Parkinson s disease symptoms; sleepiness; dizziness; worsening of Parkinson s disease; pins and needles; headache; tremors; seizure; sudden onset of sleep; restless legs syndrome; ataxia (disorder affecting co-ordination, balance and speech); distorted sense of taste; mental health disorders that affecting learning, memory, perception, and problem solving; Horner s syndrome (an eye disorder); dementia;</li><li>blurred vision; double vision; widening pupil; prolonged rolling eyes upwards; involuntary tight closure of the eyelids;</li><li>heart problems, a noticeably rapid, strong, or irregular heartbeat;</li><li>low blood pressure soon after standing up; high blood pressure; fainting; blood clot in a vein; hot flushes;</li><li>shortness of breath; difficulty in breathing; difficulty in speaking; hiccups;</li><li>stomach pains; constipation; diarrhoea; dry mouth; stomach and intestinal bleeding; stomach ulcer; difficulty in swallowing; indigestion; burning sensation in the mouth; passing wind; change in colour of saliva; more saliva than normal;</li><li>swelling of face, lips, tongue, limbs and genitals; excessive sweating; rash; severe itching of the skin; condition called Henoch-Schoenlein purpura, the symptoms of which include a purple spotted skin rash; allergic reaction causing a rash of round, red welts on the skin that itch intensely; hair loss; discoloured sweat;</li><li>muscle spasms; lockjaw;</li><li>difficulty in emptying the bladder; abnormal urine colour; loss of bladder control;</li><li>painful, abnormally long-lasting erection;</li><li>swelling of lower legs or hands; feeling weak and having no energy; feeling tired; lack of energy; difficulty in walking; chest pain;</li><li>abnormal blood investigation results; weight loss; weight gain.</li></ul><p>You may experience the following side effects:</p><ul><li><p>inability to resist the impulse to perform an action that could be harmful, which may include:</p></li><li><p>strong impulse to gamble excessively despite serious personal or family consequences;</p></li><li><p>altersed or increased sexual interest and behaviour of significant concern to you or to others, for example, an increased sexual drive;</p></li><li><p>uncontrollable excessive shopping or spending;</p></li><li><p>binge eating (eating large amounts of food in a short time period) or compulsive eating (eating more food than normal and more than is needed to satisfy your hunger).</p></li></ul><p>Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store inbrija"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store inbrija"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blisters and carton after EXP. The expiry date refers to the last day of that month.</p><p>Store below 25 C. Store in the original package in order to protect from light and moisture and only remove immediately before use.</p><p>Do not use any capsule that looks crushed, damaged or wet.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Inbrija contains</p><ul><li>The active substance is levodopa. Each hard capsule contains 42 mg levodopa. The dose that leaves the mouthpiece of the inhaler (delivered dose) is 33 mg of levodopa.</li><li>The other ingredients comprising the powder and capsule are colfosceril palmitate (DPPC), sodium chloride, hypromellose, titanium dioxide (E 171), carrageenan, potassium chloride, carnauba wax, maize starch, shellac, black iron oxide (E 172), propylene glycol and potassium hydroxide.</li></ul><p>What Inbrija looks like and contents of the pack Inbrija inhalation powder, hard capsules consist of a white powder for inhalation filled into white opaque hard capsules with A42 printed in black on the cap of the caspule and two black bands printed on the body of the capsule.</p><p>In this pack, you will find an inhaler together with peel-off blisters containing 4 hard capsules each.</p><p>The pack sizes are</p><ul><li>a carton containing 16 hard capsules (4 blister strips) and one inhaler</li><li>a carton containing 32 hard capsules (8 blister strips) and one inhaler</li><li>a carton containing 60 hard capsules (15 blister strips) and one inhaler</li><li>a carton containing 92 hard capsules (23 blister strips) and one inhaler</li></ul><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 TIreland Tel: +353 (0)1 231 4Manufacturer ADOH B.V. Godfried Bomansstraat 6543 JA Nijmegen Netherlands</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: BE, BG, CZ, DK, EE, IE, EL, FR, HR, IT, CY, LV, LT, LU, HU, MT, NL, AT, PL, PT, RO, SI, SK, FI, SE, UK-NI: Acorda Therapeutics Ireland Limited /Irsko/Irland/ /Iirimaa/Irlanti/Irlande/Irska/ rorsz g/ rland/Irlanda/Airija/ rija/L- Irlanda/Ierland/Irlandia/ rsko/Irska T l/Tel/Tel./Te ./Tlf/ /S mi/Puh: +353 (0)1 231 4DE: Esteve Pharmaceuticals GmbH Tel.: +49 30 338427-0</p><p>ES: ESTEVE PHARMACEUTICALS, S.A. Tel: +34 93 446 60 This leaflet was last revised in Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp09457b67378eccc379f945623f721bcb"/>
<resource>
<MedicinalProductDefinition>
<id value="mp09457b67378eccc379f945623f721bcb"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp09457b67378eccc379f945623f721bcb"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp09457b67378eccc379f945623f721bcb</b></p><a name="mp09457b67378eccc379f945623f721bcb"> </a><a name="hcmp09457b67378eccc379f945623f721bcb"> </a><a name="mp09457b67378eccc379f945623f721bcb-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1390/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Inbrija 33 mg inhalation powder, hard capsules</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/19/1390/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="Inbrija 33 mg inhalation powder, hard capsules"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
